心脏衰竭通过循环因素刺激瘤生长
Wouter C Meijers1, Manuel Maglione2, Stephan J L Bakker3
1Department of Cardiology (W.C.M., D.J.v.V., B.D.W., P.v.d.M., H.H.W.S., R.A.d.B.).
Circulation
|February 21, 2018
概括
心力衰竭与癌症风险增加有关. 这项研究表明HF通过心脏因素增强瘤生长,
科学领域:
- 心脏病学
- 癌症学
- 翻译医学
背景情况:
- 改善心力衰竭的生存率导致非心脏病死亡,包括癌症.
- 调查HF与癌症发展之间的潜在因果关系至关重要.
研究的目的:
- 确定心力衰竭是否会影响癌症的发展.
- 找出可能导致癌症生长的心脏因素.
主要方法:
- 使用诱导心肌梗塞的APCmin小鼠来评估瘤的生长.
- 采用异位心脏移植来隔离血动力学损伤的HF影响.
- 分析了候选分泌蛋白质及其对结肠癌细胞的影响.
- 在一般人群中与新发癌症相关的心脏和炎症生物标志物.
主要成果:
- 在小鼠中,心脏衰竭显著增加了肠道瘤负荷 (2.4倍).
- 左心室功能障碍和痕严重程度与瘤生长相关.
- 蛋白质 (serpinA3,纤维蛋白等) 的增加 在人类HF患者中发现;serpinA3促进了结肠癌细胞的增殖.
- 心脏和炎症生物标志物预测了人类的新发癌症.
结论:
- 存在心力衰竭 (HF) 增强瘤生长,独立于血液动力学因素.
- 心脏分泌的因素可能会影响HF与癌症之间的联系.
- 诊断HF应该被认为是发生癌症的危险因素.
相关概念视频
Heart Failure VI: Adjunct Therapies
395
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Heart Failure V: Medical Management
360
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360
Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Heart Failure I: Introduction
951
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K


